MINNEAPOLIS, MN--(Marketwire - July 29, 2009) -
| Highlighted Links |
MacReport Media Publishing |
E-18 Corporation |
Investor's Business Daily (IBD), which was launched in 1984, is known as one of the most innovative sources of insight and information for the investor community. IBD serves over 800,000 investors worldwide through a variety of proprietary products and services, relevant news from the investor's perspective, as well as research, investment education, efficient stock ratings and screens unavailable anywhere else (Source: Investors Business Daily - Investors.com). IBD, which is considered a research tool in the financial industry, provides critical information to retail investor that was previously only available to institutional investors.
"We hope that IBD's readers who are interested in emerging companies will follow the progress of Protectus Medical Devices," said Dr. John Salstrom, President and CEO of Protectus Medical Devices. "We believe that with the only automatic, self-sheathing safety syringe in the medical devices space, and the Company's FDA 510(k) permission to manufacture and market the device, we are well positioned to make a significant impact in the marketplace." More information about Protectus Medical Devices may be found at the Company's corporate website at www.protectusmedical.com.
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements
in the press release that relate to the Company's expectations with regard
to the future impact on the Company's results from new products in
development are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements are
subject to risks and uncertainties. Words such as "expects," "intends,"
"plans," "may," "could," "should," "anticipates," "likely," "believes" and
words of similar import also identify forward-looking statements.
Forward-looking statements are based on current facts and analyses and
other information that are based on forecasts of future results, estimates
of amounts not yet determined and assumptions of management. Readers are
urged not to place undue reliance on the forward-looking statements, which
speak only as of the date of this release. We assume no obligation to
update any forward-looking statements in order to reflect any event or
circumstance that may arise after the date of this release. Additional
information on risks and other factors that may affect the business and
financial results of E-18 Corp. can be found in the filings of E-18 Corp.
with the U.S. Securities and Exchange Commission.
Contact Information
E-18 Corp.
John Salstrom
President and CEO
moreinfo@protectusmedical.com
Ph: 800-778-8438
